(Q37202832)

18 August 2017

1 reference

title

Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV. (English)

1 reference

18 August 2017

1 reference

Josep Mallolas

1

1 reference

18 August 2017

Montserrat Laguno

series ordinal

2

1 reference

18 August 2017

publication date

1 June 2008

1 reference

Expert Review of Anti-infective Therapy

18 August 2017

published in

1 reference

18 August 2017

volume

6

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

281-289

1 reference

Highlights of the third international workshop on HIV and hepatitis coinfection.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Predictive markers of HIV and HCV infection and co-infection among inmates in a Spanish prison

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Epidemiology of viral hepatitis and HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Influence of HIV co-infection on hepatitis C immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Peginterferon-alpha(2b) and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Options for treatment of hepatitis C in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Pegylated IFNs for chronic hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Pharmacokinetics of pegylated interferons: what is misleading?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

"True" weight-based dosing versus "flat" dosing of ribavirin: will the WIN-R please come forward?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Management of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Treatment algorithm for the management of hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.281

21 January 2018

Identifiers

DOI

10.1586/14787210.6.3.281

1 reference

18 August 2017

1 reference